Osimertinib: tested on its own
65 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingNCT07295821Phase 2Report a problem
- A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical SurgeryNot yet recruitingNCT06530719Phase 2Report a problem
- Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingNCT06436144Phase 2Report a problem
- Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaRecruitingNCT06383728Phase 2Report a problem
- Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)Not yet recruitingNCT06323148Phase 3Report a problem
- Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant OsimertinibRecruitingNCT06206850Phase 2Report a problem
- Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2Report a problem
- Adjuvant Treatment Based on MRD for EGFR Mutant NSCLCRecruitingNCT05536505Phase 2Report a problem
- Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingNCT05528458Phase 2Report a problem
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR MutationsRecruitingNCT04816838Not applicableReport a problem
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingNCT04591002Phase 2Report a problem
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingNCT03191149Phase 2Report a problem
- Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingNCT06303167Phase 2Results postedReport a problem
- Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCTerminatedNCT05215951Phase 2Results postedReport a problem
- A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04765059Phase 3Results postedReport a problem
- Osimertinib Study in Indian PatientsCompletedNCT03853551Phase 4Results postedReport a problem
- A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsCompletedNCT03434418Phase 2Results postedReport a problem
- Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryActive, not recruitingNCT03433469Phase 2Results postedReport a problem
- Osimertinib for NSCLC With EGFR Exon 20 Insertion MutationCompletedNCT03414814Phase 2Results postedReport a problem
- A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompletedNCT03239340Phase 2Results postedReport a problem
- T790M Plasma Testing Methodology Comparison and Clinical ValidationCompletedNCT02997501Phase 3Results postedReport a problem
- Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MCompletedNCT02841579Phase 2Results postedReport a problem
- Phase I, Study in Chinese NSCLC PatientsCompletedNCT02529995Phase 1Results postedReport a problem
- A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291CompletedNCT02491944Phase 1Results postedReport a problem
- Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCCompletedNCT02474355Phase 3Results postedReport a problem
- Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompletedNCT02442349Phase 2Results postedReport a problem
- Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy VolunteersCompletedNCT02224053Phase 1Results postedReport a problem
- Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results postedReport a problem
- Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in VolunteersCompletedNCT02096679Phase 1Results postedReport a problem
- Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursCompletedNCT02094261Phase 2Results postedReport a problem
- AZD9291 First Time In Patients Ascending Dose StudyCompletedNCT01802632Phase 1/2Results postedReport a problem
- Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.Status unknownNCT05785208Phase 4Report a problem
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingNCT05629234Phase 3Report a problem
- Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2Report a problem
- Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCStatus unknownNCT05458726Phase 2Report a problem
- A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3Report a problem
- Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyActive, not recruitingNCT05089916Phase 2Report a problem
- Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)Status unknownNCT05085054Phase 2Report a problem
- Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerStatus unknownNCT04974879Phase 2Report a problem
- Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)TerminatedNCT04908956Phase 2Report a problem
- Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedNCT04563871Phase 2Report a problem
- Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationCompletedNCT04233021Phase 2Report a problem
- Whole Genomic Landscape of Advanced EGFR-mutant NSCLCActive, not recruitingNCT03969823Not applicableReport a problem
- MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtibActive, not recruitingNCT03865511Phase 2Report a problem
- Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)CompletedNCT03810066Phase 2Report a problem
- First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung CancerActive, not recruitingNCT03804580Phase 2Report a problem
- 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompletedNCT03732352Phase 2Report a problem
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLCActive, not recruitingNCT03667820Phase 2Report a problem
- Osimertinib In EGFR Mutant Lung CancerActive, not recruitingNCT03586453Phase 2Report a problem
- Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLCCompletedNCT03535363Phase 1Report a problem
- Osimertinib as First-line Therapy for Patients With Late-stage Lung CancerStatus unknownNCT03460275Phase 2Report a problem
- Uncommon EGFR AZD9291Status unknownNCT03424759Phase 2Report a problem
- TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid BiopsyCompletedNCT03394118Phase 2Report a problem
- Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSStatus unknownNCT03257124Phase 2Report a problem
- Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3Report a problem
- Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerCompletedNCT02959749Phase 2/3Report a problem
- Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1Report a problem
- Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLCStatus unknownNCT02824952Phase 2Report a problem
- Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAStatus unknownNCT02811354Phase 2Report a problem
- Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCStatus unknownNCT02771314Phase 2Report a problem
- Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNACompletedNCT02769286Phase 2Report a problem
- Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain MetastasesStatus unknownNCT02736513Phase 2Report a problem
- AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesStatus unknownNCT02504346Phase 2Report a problem
- Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT02161770Phase 1Report a problem
- To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.CompletedNCT01951599Phase 1Report a problem